

INFORME DE BÚSQUEDA DE PATENTES				
N° de solicitud: 15301138				
CRITERIOS PARA LA BÚSQUEDA (Anexar pantallazo o reporte en PDF, junto con los boléanos utilizados*. Para el caso de secuencias, anexar alineamientos)				
Palabras clave utilizadas		Anti-LOX-1/LOXIN/OLR1/Lectin-like oxidized LDL receptor 1 antibodies, claudication Rutherford Class II/III, angina.		
CLASIFICACIONES UTILIZADAS PARA LA BÚSQUEDA		CIP: C07K 16/28		
		CPC (Opcional): -		
DOCUMENTOS CONSIDERADOS RELEVANTES (documentos patentes, literatura no patente, etc...)				
Informes/Base de datos	N° de solicitud/ Autor**	Fecha de Publicación/ Presentación (DD/MM/AAAA)	Reiv. afectadas (Con indicación, si procede, de las partes relevantes o números de secuencias)	Categorías especiales de los documentos citados***
SIPI	No hay registros que puedan afectar la patentabilidad de la solicitud.	-	-	-
EPO (11/11/2014)	Xu X, Gao X, Potter B J, Cao J M, Zhang C. 2007. Anti-LOX-1 rescues endothelial function in coronary arterioles in atherosclerotic ApoE knockout mice. ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 20070401 HIGHWIRE PRESS, PHILADELPHIA, PA, US. Vol: 27, Nr: 4, Page(s): 871 – 877.	-	-	A
	EP2444492	25/04/2012	-	A
	EP1418234	12/05/2004	-	A
	EP2048161	15/04/2009	-	A
	WO2012/009709	19/01/2012	-	A
	Ohki I, Ishigaki T, Oyama T, Matsunaga S, Xie Q, Ohnishi-Kameyama M, Murata T, Tsuchiya D, Machida S, Morikawa K, Tate S. 2005. Crystal Structure of Human Lectin-like, Oxidized Low-Density Lipoprotein Receptor 1 Ligand Binding Domain and Its Ligand Recognition Mode to OxLDL. Struc, ELSEVIER, AMSTERDAM, NL. Vol: 13, Nr: 6, Page(s): 905 – 917.	01/06/2005	-	A

Patbase*	US2003143226	31/07/2003	-	A
	US20090298918	03/12/2009	-	A
	US20090203039	13/08/2009	-	A
	US20080267984	30/10/2008	-	A
	US20090311271	17/12/2009	-	A
	US20120087926	12/04/2012	-	A
	US2014377281	25/12/2014	-	-
	US20150004168	01/01/2015	-	-
*** Categorías especiales de documentos citados:				
“A” documento que define el estado general de la técnica no considerado como particularmente relevante.		“X” documento particularmente relevante; la invención reivindicada no puede considerarse nueva o que implique una actividad inventiva por referencia al documento aisladamente considerado.		
“E” solicitud de patente o patente anterior pero publicada en la fecha de presentación internacional o en fecha posterior.		“Y” documento particularmente relevante; la invención reivindicada no puede considerarse que implique una actividad inventiva cuando el documento se asocia a otro u otros documentos de la misma naturaleza, cuya combinación resulta evidente para un experto en la materia.		
“P” documento publicado antes de la fecha de presentación internacional pero con posterioridad a la fecha de prioridad reivindicada.				
**** Indicar entre paréntesis la Autoridad que realizó la búsqueda o el informe preliminar Ejs: EPO, JP, INAPI.				

Fecha del reporte de búsqueda:	06/06/2017
--------------------------------	------------

Búsqueda en PatBase



Username: SIC3@patbase.com
 Subaccount: Mario Forero

Menu - Search - History - Session - Folder - Order - Help - Logout

#	Search query	Results	Options
1	TAC=(antibod* and (LOX1 OR LOX-1 OR LOXIN OR OLR1 OR (LOW DENSITY LIPOPROTEIN OXIDIZED RECEPTOR 1))) and CPC=(C07K)	47	View Browse Hits Optimise more...

Information | Shortcuts

Command Reference

- Bibliographic data
- Textual data
- Update commands
- Operators
- Navigation / shortcuts

4) Family number: 29488523 (US2003143226A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] HUMAN MONOCLONAL **ANTIBODIES** AGAINST OXIDIZED LDL RECEPTOR AND MEDICINAL USE THEREOF

Abstract: Source: US2003143226A [EN] Various human monoclonal **antibodies** that bind to human **LOX-1** and inhibit the binding of in-vivo **LOX-1** ligands to **LOX-1**, and the **LOX-1**-mediated incorporation of the ligands into cells, were obtained by immunizing human **antibody**-producing transgenic mice (created by genetic engineering) with soluble human oxidized LDL receptor (**LOX-1**). Furthermore, the human monoclonal **antibodies** were found to be effective in preventing and treating a variety of diseases.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K39/395 A61P13/12 A61P29/00 A61P3/06 A61P43/00 A61P7/00 A61P7/02 A61P7/04 A61P9/10 C07K16/28 C12N1/21 C12N15/09 C12N15/12 C12N5/06 C12N5/10 C12N5/16 C12P21/08 (Advanced/Invention); A61P29/00 A61P43/00 C07K14/705 C12N1/21 C12N15/02 C12N15/09 C12N15/13 C12P21/08 (Advanced/Non-invention); A61K39/395 A61P13/00 A61P29/00 A61P43/00 A61P7/00 A61P9/00 C07K16/18 C12N1/21 C12N15/09 C12N5/06 C12N5/10 C12P21/08 (Core/Invention)

International (IPC 1-7): A61K39/395 A61P13/12 A61P29/00 A61P43/00 A61P7/02 A61P7/04 A61P9/10 C07K16/28 C12N1/21 C12N15/09 C12N15/12 C12N5/06 C12N5/10 C12P21/08


CPC: C07K16/28 A01K2217/075 A61K2039/505 C07K2317/21

European: C07K16/28 K01K217/07B K61K39/505 M07K209/00 M07K317/210

US: 424/133.1 424/133.100P 424/143.1 424/143.100P 424/143.100S 435/325 435/325S 435/334 435/334S 530/388.15 530/388.150S 530/388.22 530/388.220S

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU200136063 A5	20010912	AU20010036063	20010302	
AU2006203702 AA	20061019	AU20060203702	20060825	
AU2006203702 BB	20090716	AU20060203702	20060825	
AU784677 B2	20060525	AU20010036063	20010302	
CA2401993 AA	20020830	CA20012401993	20010302	
EP1418234 A1	20040512	EP20010908263	20010302	



9) Family number: 34033577 (US2009298918A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] ALTERNATIVE SPLICING ISOFORM OF LOX-1 PROTEIN ENCODING GENE, AND USES THEREOF

Abstract: Source: US2009298918A [EN] The invention relates to a new alternative splicing isoform of **QLR1** gene encoding for the **LOX-1** protein, uses and methods related to the treatment and to the prediction of the risk of cardiovascular diseases.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K31/7105 A61K31/711 A61K35/76 A61K38/00 A61K48/00 A61P9/00 A61P9/10 C07H21/04 C07K14/705 C12N15/09 C12Q1/68 (Advanced/Invention);

A61K31/7105 A61K31/711 A61K35/66 A61K38/00 A61K48/00 A61P9/00 C07H21/00 C07K14/435 C12N15/09 C12Q1/68 (Core/Invention)


CPC: C12Q2600/156 C12Q2600/172 C12Q1/6883 C07K14/7056 C12Q2600/156

European: C07K14/705F C12Q1/68M6

US: 435/6 435/6.11 435/6.110S 435/6S 514/44.00RP 514/44R 536/24.3 536/24.300S

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
DE602006037747 D1	20131002	DE20060037747T	20060620	
EP1893775 A2	20080305	EP20060766347	20060620	
EP1893775 B1	20130807	EP20060766347	20060620	
ITRM20050325 A1	20061224	IT2005RM00325	20050623	
JP2009502119 T2	20090129	JP20080517705T	20060620	
US2009298918 AA	20091203	US20060922877	20060620	
WO06137101 A2	20061228	WO2006IT00470	20060620	
WO06137101 A3	20070531	WO2006IT00470	20060620	
WO06137101 B1	20070705	WO2006IT00470	20060620	



12) Family number: 41178172 (US2009203039A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] MONOCLONAL ANTIBODY TO SOLUBLE **LOX-1**

Abstract: Source: US2009203039A [EN] It is intended to provide a monoclonal **antibody** that specifically recognizes human soluble **LOX-1**, particularly a monoclonal **antibody** with a dissociation constant (Kd) for human soluble **LOX-1** of 1x10-9 (M) or less. The **antibody** can be produced from a hybridoma prepared by a method including the following steps of: (1) immunizing a non-human animal with a prokaryotic cell-derived human **LOX-1** extracellular domain; (2) collecting **antibody**-producing cells from the animal; (3) fusing the **antibody**-producing cells with myeloma cells; (4) selecting hybridomas that produce a monoclonal **antibody** reacting with the human **LOX-1** extracellular domain from the fused cells obtained in the above step; and (5) selecting a hybridoma that produces a monoclonal **antibody** reacting with a eukaryotic cell-derived human **LOX-1** extracellular domain from the selected hybridomas.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K39/395 C07K16/00 C07K16/28 C12N5/06 C12N5/07 C12N5/10 C12N5/12 C12N5/16 C12N5/20 C12P21/08 G01N33/15 G01N33/50 G01N33/53 G01N33/577 (Advanced/Invention);

C07K16/28 C12N15/02 C12N5/12 C12P21/08 (Advanced/Non-invention);

C07K16/00 C07K16/18 C12N5/06 C12N5/10 C12P21/08 G01N33/53 (Core/Invention)

International (IPC 1-7): C07K16/28


CPC: C07K16/28 C07K231/92

European: C07K16/28 M07K317/920

US: 435/326 435/331 435/331S 435/7.1 435/7.100P 530/387.9 530/387.900S 530/388.1

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2007277684 AA	20080131	AU20070277684	20070727	
AU2007277684 BB	20121108	AU20070277684	20070727	
CA2660947 AA	20090127	CA20072660947	20070727	
CN101522715 A	20090902	CN200780036077	20070727	
CN101522715 B	20130320	CN200780036077	20070727	
CN102675461 A	20120919	CN201110363199	20070727	



12) Family number: 41178172 (US2009203039A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] MONOCLONAL ANTIBODY TO SOLUBLE **LOX-1**

Abstract: Source: US2009203039A [EN] It is intended to provide a monoclonal **antibody** that specifically recognizes human soluble **LOX-1**, particularly a monoclonal **antibody** with a dissociation constant (Kd) for human soluble **LOX-1** of 1x10-9 (M) or less. The **antibody** can be produced from a hybridoma prepared by a method including the following steps of: (1) immunizing a non-human animal with a prokaryotic cell-derived human **LOX-1** extracellular domain; (2) collecting **antibody**-producing cells from the animal; (3) fusing the **antibody**-producing cells with myeloma cells; (4) selecting hybridomas that produce a monoclonal **antibody** reacting with the human **LOX-1** extracellular domain from the fused cells obtained in the above step; and (5) selecting a hybridoma that produces a monoclonal **antibody** reacting with a eukaryotic cell-derived human **LOX-1** extracellular domain from the selected hybridomas.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K39/395 C07K16/00 C07K16/28 C12N5/06 C12N5/07 C12N5/10 C12N5/12 C12N5/16 C12N5/20 C12P21/08 G01N33/15 G01N33/50 G01N33/53 G01N33/577 (Advanced/Invention);

C07K16/28 C12N15/02 C12N5/12 C12P21/08 (Advanced/Non-invention);

C07K16/00 C07K16/18 C12N5/06 C12N5/10 C12P21/08 G01N33/53 (Core/Invention)

International (IPC 1-7): C07K16/28


CPC: C07K16/28 C07K231/92

European: C07K16/28 M07K317/920

US: 435/326 435/331 435/331S 435/7.1 435/7.100P 530/387.9 530/387.900S 530/388.1

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AU2007277684 AA	20080131	AU20070277684	20070727	
AU2007277684 BB	20121108	AU20070277684	20070727	
CA2660947 AA	20090127	CA20072660947	20070727	
CN101522715 A	20090902	CN200780036077	20070727	
CN101522715 B	20130320	CN200780036077	20070727	
CN102675461 A	20120919	CN201110363199	20070727	



14) Family number: 42117208 (US2008267984A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS THROUGH DENDRITIC CELL LECTIN-LIKE OXIDIZED LDL RECEPTOR-1 (LOX-1)

Abstract: Source: US2008267984A [EN] The present invention includes compositions and methods for targeting the LOX-1 receptor on immune cells and uses for the anti-LOX-1 antibodies.

Classifications: Classification Explorer

International (IPC): A61K 39/395 A61K 39/385 A61K 39/39 A61K 39/395 A61K 47/48 A61P 1/04 A61P 1/16 A61P 11/00 A61P 11/06 A61P 17/00 A61P 17/06 A61P 17/14 A61P 19/02 A61P 21/04 A61P 25/00 A61P 27/02 A61P 27/16 A61P 29/00 A61P 31/00 A61P 31/04 A61P 31/10 A61P 31/12 A61P 33/00 A61P 33/02 A61P 35/00 A61P 37/00 A61P 37/02 A61P 37/04 A61P 37/06 A61P 37/08 A61P 43/00 A61P 7/04 A61P 7/06 C07K 14/47 C07K 16/00 C07K 16/18 C07K 16/28 C07K 16/46 C07K 17/00 C07K 17/14 C07K 19/00 C12N 15/09 C12N 5/06 C12N 5/071 C12N 5/078 C12N 5/0781 C12N 5/0784 C12N 5/16 C12P 21/08 (Advanced/Invention); A61K 39/00 (Advanced/Non-invention);

A61K 39/00 A61K 39/39 A61K 39/395 A61P 1/00 A61P 11/00 A61P 17/00 A61P 19/00 A61P 21/00 A61P 25/00 A61P 27/00 A61P 29/00 A61P 31/00 A61P 33/00 A61P 35/00 A61P 37/00 A61P 43/00 A61P 7/00 C07K 14/435 C07K 16/00 C07K 16/18 C07K 16/46 C12N 15/09 C12N 5/06 C12N 5/078 C12N 5/0781 C12N 5/0784 (Core/Invention); A61K 39/395 C07K 16/28 (Core/Non-invention);

A61K C07K (Subclass/Invention)


CPC: A61K 47/48369 A61K 2039/55516 C07K 16/28 C07K 2317/92 C07K 2319/01 C07K 2319/33 A61K 2039/5154

European: C07K 16/28 K61K 39/555B1 M07K 317/920 M07K 319/01 M07K 319/33

US: 1/1 424/184.1 424/184.100P 435/326 435/326S 435/372 435/375 435/375S 530/387.1 530/387.100S 530/388.7 530/391.1

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
AU2008218190 AA	20080828	AU20080218190	20080222	📄 🔍 🔗
AU2008218190 BB	20121101	AU20080218190	20080222	📄 🔍 🔗
AU2008218190 CA	20130502	AU20080218190	20080222	📄 🔍 🔗
AU2012261623 AA	20130110	AU20120261623	20121210	📄 🔍 🔗



19) Family number: 44124690 (US2009311271A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] METHODS AND COMPOSITIONS FOR SELECTIVE INHIBITION OF LIGAND BINDING TO THE LECTIN-LIKE RECEPTOR FOR OXIDIZED LOW DENSITY LIPOPROTEIN (LOX-1)

Abstract: Source: US2009311271A [EN] The present invention provides methods of selectively inhibiting the binding of one ligand for LOX-1, but not one other ligand for LOX-1. Moreover, the invention relates to the identification of binding partners that act in a selective manner to inhibit the binding of one ligand to LOX-1, but not one other ligand for LOX-1, and methods of identifying such binding partners. Pharmaceutical compositions comprising the binding partners for LOX-1, in particular, anti-LOX-1 antibodies or fragments thereof, are also provided in the present invention.

Classifications: Classification Explorer

International (IPC): A61K 39/395 C07K 16/18 C12N 1/20 C12N 5/06 (Advanced/Invention)

CPC: C07K 16/28 C07K 16/2851 C07K 2317/56 C07K 2319/30

European: C07K 16/28 C07K 16/28C M07K 317/560 M07K 319/30

US: 424/172.1 424/172.100P 435/252.1 435/252.100S 435/375 435/375S 530/387.1 530/387.100S

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
US2009311271 AA	20091217	US20090473812	20090528	📄 🔍 🔗

Priority: Priority Map

US20080057005P 20080529 US20080075084P 20080624 US20090473812 20090528


Probable Assignee: WYETH

Assignee(s): (std): WYETH CORP

Assignee(s): WYETH

Inventor(s): (std): HARNISH DOUGLAS CARL ; JIN MACY XIAOHANG ; ZHANG SONGWEN

Agent(s): WYETH, PATENT LAW GROUP; WYETH PATENT LAW GROUP



22) Family number: 47898241 (US2012087926A)

Similar • Translate • Full-text • Status • Citations

Title: [EN] CHICKEN-DERIVED ANTI-LOX-1 ANTIBODY

Abstract: Source: US2012087926A [EN] Anti-LOX-1 antibodies having higher efficiency in action and excellent cross-reactivity are obtained. The anti-LOX-1 antibodies having higher efficiency in action and excellent cross-reactivity have been obtained, the antibodies being which specifically binds to a LOX-1 and having heavy chain CDR3 comprising one or more amino acid sequences selected from the group consisting of a) an amino acid sequence set forth in SEQ ID NO: 1, b) an amino acid sequence having 80 percent or more homology to the amino acid sequence a), c) an amino acid sequence having one or several amino acid deletions, substitutions, or additions in the amino acid sequence a), and d) an amino acid sequence encoded by a nucleotide sequence of a nucleic acid chain hybridizing under a stringent condition with a nucleic acid chain having a nucleotide sequence complementary to a nucleotide sequence encoding the amino acid sequence a).

Classifications: Classification Explorer

International (IPC): A61K 39/395 A61P 29/00 A61P 7/00 A61P 7/02 A61P 9/00 A61P 19/10 C07H 21/00 C07K 16/28 C12N 15/09 C12N 5/071 (Advanced/Invention)

CPC: C07K 16/28 C07K 2317/23 C07K 2317/565 C07K 2317/622 C07K 2317/92


European: C07K 16/28 M07K 317/230 M07K 317/565 M07K 317/622 M07K 317/920

US: 424/143.1 424/143.100P 435/375 435/375S 530/388.22 530/388.220S 530/389.1 530/389.100S 536/23.53 536/23.530S

Family: Family Explorer

Publication number	Publication date	Application number	Application date	Links
EP2444492 A1	20120425	EP20100789545	20100617	📄 🔍 🔗
EP2444492 A4	20131218	EP20100789545	20100617	📄 🔍 🔗
EP2444492 A9	20120725	EP20100789545	20100617	📄 🔍 🔗
JP2010147171 A1	20121206	JP20110519630T	20100617	📄 🔍 🔗
US2012087926 AA	20120412	US20100378554	20100617	📄 🔍 🔗
WO10147171 A1	20101223	WO2010JP60266	20100617	📄 🔍 🔗

Priority: Priority Map



Title: [EN] LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 **ANTIBODIES** AND METHODS OF USE


Abstract: Source: US2014377281A [EN] The present invention relates to monoclonal **antibodies** binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as **LOX-1**), and pharmaceutical compositions and methods of treatment comprising the same.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K39/00 A61K39/395 A61P17/06 A61P19/02 A61P27/02 A61P29/00 A61P37/02 A61P39/06 A61P43/00 A61P9/00 A61P9/10 A61P9/14 C07K16/28 C12N15/09 (Advanced/Invention);
A61P9/10 C07K14/47 (Advanced/Non-invention);
CPC: C07K16/2851 A61K2039/505 A61K39/395 C07K14/33 C07K14/4726 C07K16/28 C07K2317/21 C07K2317/33 C07K2317/565 C07K2317/76 C07K2317/92
US: 424/172.1 530/389.1

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AR096651 AA	20160127	AR2014P102313	20140619	
AU2014281294 AA	20141224	AU20140281294	20140620	
AU2014281294 AB	20160204	AU20140281294	20140620	
CA2915831 AA	20151216	CA20142915831	20140620	
CN105518026 A	20160420	CN201480046090	20140620	
EA201690064 A1	20160531	EA20160090064	20140620	
EP3010936 A2	20160427	EP20140738994	20140620	
IN11993DN2015 A	20160812	IN2015DN11993	20151231	
JP2016523257 T2	20160808	JP20160521832T	20140620	
KR20160021849 A	20160226	KR20167001385	20140620	
MX2015017853 A1	20160510	MX20150017853	20140620	



Title: [EN] LECTIN-LIKE OXIDIZED LDL RECEPTOR 1 **ANTIBODIES** AND METHODS OF USE

Abstract: Source: US2015004168A [EN] The present invention relates to monoclonal **antibodies** binding to human lectin-like oxidized LDL (low density lipoprotein) receptor 1 (hereinafter, sometimes referred to as **LOX-1**), and pharmaceutical compositions and methods of treatment comprising the same.

Classifications: [Classification Explorer](#)

International (IPC 8-9): A61K39/00 A61K39/395 A61K45/06 A61K9/00 A61P43/00 A61P7/02 A61P9/00 A61P9/10 C07K C07K16/28 C12N15/09 (Advanced/Invention);
A61K39/00 A61P9/10 C07K14/47 (Advanced/Non-invention);
C07K (Subclass/Invention);
CPC: C07K16/28 C07K2317/21 C07K2317/76 A61K2039/505 C07K16/2851 C07K2317/565 A61K39/395 C07K14/4726 C07K2317/33 C07K2317/34 C07K2317/92 A61K45/06 A61K9/0019
US: 424/139.1 530/387.9

Family: [Family Explorer](#)

Publication number	Publication date	Application number	Application date	Links
AP201508952 A0	20151231	AP20150008952	20140620	
AR096601 AA	20160120	AR2014P102255	20140613	
AU2014281292 AA	20141224	AU20140281292	20140620	
CA2915970 AA	20151217	CA20142915970	20140620	
CL2015003642 A1	20160722	CL20150003642	20151216	
CN105492462 A	20160413	CN201480044171	20140620	
CO15301138 A2	20160630	CO20150301138	20151218	
CR20150668 A	20160729	CR20150000668	20151217	
CU20150181 A7	20160729	CU20150000181	20151218	
EA201690032 A1	20160630	EA20160090032	20140620	

